AOD-9604 Adolescent (12-17) Monitoring: What Clinicians and Families Need to Know

What Is AOD-9604 and Why Is Its Adolescent Use So Complicated?

AOD-9604 is a synthetic peptide comprising amino acids 176-191 of the human growth hormone sequence. Heffernan et al. demonstrated in 2001 that this fragment drives lipolysis in adipose tissue without activating the canonical GH receptor, at least in animal models [1]. That single mechanistic finding has become the entire scientific rationale for off-label clinical use. No Phase III human trial exists. The FDA has never approved AOD-9604 for any indication in any age group, and the agency's 2015 decision to remove it from the bulk drug substances list for 503B outsourcing facilities underscored its unproven status [2]. Adolescents aged 12-17 sit at a uniquely vulnerable intersection: they are undergoing rapid skeletal growth, hormonal flux of puberty, and neurological maturation that extends into the early twenties. Introducing any peptide that shares sequence homology with growth hormone into that milieu demands a monitoring structure that most peptide-prescribing practices do not currently apply.

The compounding pathway under 503A allows individual patient-specific prescriptions, but it does not generate safety data. Prescribers who use 503A compounding pharmacies for AOD-9604 in adolescents are operating entirely outside evidence-based guidelines from the Pediatric Endocrine Society [3] and the American Academy of Pediatrics [4]. That is not a reason to refuse all clinical engagement with families who present asking questions. It is a reason to build the most thorough monitoring protocol possible if a prescribing decision is made.

The Regulatory and Legal Baseline Every Prescriber Must Establish First

Before initiating AOD-9604 in any patient aged 12-17, the prescriber must document three things: the specific off-label rationale, informed parental or guardian consent, and written adolescent assent. The FDA's framework for pediatric informed consent aligns with 21 CFR Part 50, Subpart D, which governs research involving children [5]. Even in clinical (non-research) settings, those standards represent the ethical floor. A verbal conversation is not sufficient. The prescriber's chart note must record BMI percentile at baseline (using CDC growth charts [6]), the clinical reasoning that led to the prescribing decision, and explicit documentation that no FDA-approved alternative was available or acceptable.

The Endocrine Society's clinical practice guidelines on obesity pharmacotherapy do not endorse any peptide-based agent for adolescents as of their 2023 update [7]. The one agent with genuine Phase III data in adolescents aged 12-17 is semaglutide 2.4 mg: STEP TEENS (N=201) showed 16.1% mean body weight reduction at 68 weeks versus 0.6% with placebo (P<0.001) [8]. Families asking about AOD-9604 should receive that comparison explicitly. If the decision still proceeds to AOD-9604, the monitoring protocol below applies from day one.

Growth Velocity Monitoring: The Non-Negotiable Core

Growth velocity is the single most important safety parameter in any adolescent receiving a peptide with partial GH-sequence homology. Normal growth velocity in early puberty (Tanner stage II-III) ranges from approximately 6 to 11 cm per year, depending on sex and pubertal timing [9]. Any deviation of more than 2 cm per year above the patient's prior trajectory warrants immediate endocrinology referral and bone age imaging.

Bone age should be assessed by plain radiograph of the left hand and wrist using the Greulich-Pyle atlas before treatment begins. Repeat imaging every 6 months while epiphyseal plates remain open. A bone age that advances more than 1.5 years beyond chronological age in any 6-month interval is a hard stop. Continue the patient on whatever monitoring schedule endocrinology recommends, but AOD-9604 should not be continued while that evaluation is pending.

Standing height must be measured with a wall-mounted stadiometer (not a door-frame mark) at every clinical visit. Record Tanner stage at each visit. The Pediatric Endocrine Society recommends formal pubertal staging documentation at every encounter where a growth-altering agent is being used [3]. That standard applies here.

Metabolic and Endocrine Panel: Frequency and Specific Markers

The purported mechanism of AOD-9604 involves lipolysis via beta-3 adrenergic receptor pathways and PPAR-gamma modulation in animal studies [1]. Human data on insulin sensitivity effects are absent, which means the risk of insulin resistance cannot be quantified. Adolescents with obesity already carry elevated baseline risk: data from the NHANES 2017-2020 cycle show that 28.7% of US adolescents aged 12-19 met criteria for insulin resistance defined by HOMA-IR greater than 2.5 [10]. That background prevalence justifies aggressive baseline and follow-up metabolic screening.

Obtain the following at baseline:

• Fasting glucose and fasting insulin (to calculate HOMA-IR)
• HbA1c
• Fasting lipid panel (total cholesterol, LDL, HDL, triglycerides)
• Comprehensive metabolic panel including AST, ALT, creatinine
• IGF-1 and IGFBP-3 (to establish a pre-treatment GH-axis reference)
• Thyroid panel: TSH, free T4

Repeat fasting glucose, fasting insulin, and HOMA-IR at 8 weeks. If HOMA-IR has risen by more than 0.5 points from baseline, reassess the risk-benefit ratio before continuing. Repeat the full metabolic panel at 12 weeks and every 12 weeks thereafter for the duration of treatment. Repeat IGF-1 at 12 weeks and every 6 months. Any IGF-1 elevation above the age- and sex-adjusted 97th percentile is a hard stop pending endocrinology consultation.

Liver enzyme elevation above three times the upper limit of normal on any single draw also warrants discontinuation and hepatology referral, consistent with general hepatotoxicity surveillance standards used in pediatric pharmacotherapy trials [11].

IGF-1 and the GH-Axis: Why This Specific Biomarker Matters Most

The original Heffernan 2001 paper showed that AOD-9604 in obese mice produced significant fat-pad reduction without the diabetogenic effects associated with full-length GH [1]. The mechanism appeared to bypass the GH receptor. In human adolescents, however, the GH axis is already in a state of high physiological activity. IGF-1 levels peak during mid-puberty, often reaching 400-600 ng/mL in otherwise healthy adolescents [12]. Introducing any exogenous peptide with GH sequence homology into that background creates a plausible, if unquantified, risk of additive IGF-1 stimulation through paracrine or indirect pathways not captured in the original rodent model.

The Growth Hormone Research Society's 2019 consensus statement on IGF-1 monitoring states: "Any pharmacological intervention that could plausibly alter GH-axis signaling in a growing child or adolescent requires pre-treatment and serial post-treatment IGF-1 measurement at intervals no longer than 6 months." [13] AOD-9604 fits that criterion. Treat any IGF-1 result above the lab's age-specific reference range as actionable, not merely noteworthy.

Mental Health Monitoring: An Underappreciated Component

Adolescents seeking or being offered weight-related interventions carry disproportionate rates of depression, anxiety, and disordered eating. The 2022 US Preventive Services Task Force recommendation on anxiety screening in adolescents aged 8-18 calls for routine screening in primary care settings [14]. Any practice prescribing AOD-9604 to adolescents must integrate mental health screening into the monitoring schedule, not treat it as optional.

Use the PHQ-A (Adolescent version of the Patient Health Questionnaire) at baseline and every 3 months. Use the SCOFF questionnaire or the EDE-Q adapted for adolescents to screen for disordered eating at baseline and at 6-month intervals. Body image concerns often intensify when adolescents are placed on any weight-loss-adjacent therapy. Document screening scores in the chart. A PHQ-A score of 11 or higher warrants same-visit mental health referral [15].

The American Academy of Pediatrics' 2023 clinical practice guideline on obesity in children and adolescents explicitly notes that weight management interventions should be embedded within a broader framework that includes mental health support [4]. That guidance does not carve out an exception for compounded peptides.

Injection Site and Local Reaction Monitoring

AOD-9604 is administered as a subcutaneous injection, typically once daily. Adolescents and their caregivers must be trained on aseptic technique before the first dose. Injection sites should be rotated across the abdomen, lateral thigh, and lateral upper arm. Document the primary injection site at each visit. Ask specifically about:

• Nodule formation or persistent induration
• Erythema lasting more than 48 hours
• Skin hyperpigmentation or atrophy at injection sites
• Systemic reactions within 30 minutes of injection (flushing, palpitations, lightheadedness)

Local lipoatrophy at injection sites is a recognized risk with repeated subcutaneous injections of peptide compounds [16]. In adolescents, cosmetically visible lipoatrophy carries significant psychological weight and must be addressed immediately if detected.

FDA MedWatch reporting (www.fda.gov/safety/medwatch) is required for any serious adverse event associated with a compounded drug, including compounded AOD-9604 [2]. Prescribers should document that they have counseled families on this reporting pathway.

Cardiovascular and Blood Pressure Monitoring

Resting blood pressure and heart rate at every visit. Adolescent hypertension thresholds follow the 2017 American Academy of Pediatrics clinical practice guideline on pediatric hypertension, which defines Stage 1 hypertension as systolic blood pressure at or above the 95th percentile for age, sex, and height on three separate occasions [17]. Any AOD-9604 prescribing practice should have age-sex-height blood pressure tables available at the point of care.

Obtain a resting ECG at baseline if the adolescent has any personal or family history of arrhythmia, cardiomyopathy, or unexplained syncope. Animal data on GH-fragment peptides and cardiac tissue do not raise a specific arrhythmia signal, but the absence of human trial data makes a baseline ECG reasonable practice in this age group.

Laboratory and Imaging Schedule: Summary Table

The monitoring frequency below synthesizes the guidance above into a single actionable framework.

Baseline (before first dose)

• Standing height, weight, BMI percentile (CDC reference)
• Tanner stage assessment
• Bone age X-ray (left hand, Greulich-Pyle)
• Fasting glucose, fasting insulin, HOMA-IR
• HbA1c
• Fasting lipid panel
• Comprehensive metabolic panel (CMP)
• IGF-1, IGFBP-3
• TSH, free T4
• PHQ-A mental health screen
• SCOFF disordered eating screen
• Resting blood pressure and heart rate
• ECG (if cardiac history present)

Week 8

• Fasting glucose, fasting insulin, HOMA-IR
• Blood pressure, heart rate
• Injection site assessment
• PHQ-A

Week 12

• Full metabolic panel (repeat baseline labs except bone age and TSH)
• IGF-1
• PHQ-A
• Growth velocity calculation (height measurement mandatory)
• Tanner stage reassessment

Every 12 weeks thereafter

• Full metabolic panel
• Blood pressure, heart rate
• Injection site assessment
• PHQ-A

Every 6 months

• IGF-1, IGFBP-3
• Bone age X-ray (while growth plates open)
• SCOFF disordered eating screen
• Formal growth velocity calculation against Tanner-stage norms

When to Discontinue: Hard-Stop Criteria

Some findings require immediate discontinuation, not a wait-and-reassess approach. Discontinue AOD-9604 and refer to pediatric endocrinology if any of the following occur:

• Bone age advance of more than 1.5 years in any 6-month period
• Growth velocity acceleration of more than 2 cm per year above prior trajectory
• IGF-1 above the age-sex-adjusted 97th percentile on any two consecutive measurements
• HOMA-IR rise of 1.0 or more points from baseline at any measurement point
• Liver enzymes (AST or ALT) exceeding three times the upper limit of normal
• New or worsening hypertension meeting Stage 1 pediatric criteria on two consecutive visits
• PHQ-A score of 15 or higher (severe depression threshold) at any visit
• Any anaphylactic or serious injection-site reaction

The Pediatric Endocrine Society position on unapproved growth-related pharmacotherapy states: "The burden of proof for safety lies with the prescriber, not with the absence of a harm signal in the literature." [3] Absence of published adverse events in adolescents reflects absent data, not confirmed safety.

Communicating Risk to Adolescents and Their Families

Informed assent from the minor, separate from parental consent, is an ethical requirement for adolescents aged 12 and older, per the American Academy of Pediatrics' policy on informed consent [18]. The conversation must be age-appropriate and must cover four points explicitly:

1. No controlled human trial has tested AOD-9604 in anyone aged 12-17.
2. The drug's effect on growth plates and pubertal development is unknown.
3. Monitoring will be frequent and will include blood draws and X-rays.
4. The drug will be stopped immediately if any safety signal appears.

Document this conversation with the minor present. Use plain language. The American Academy of Pediatrics recommends that clinicians use a teach-back method to confirm adolescent understanding of any treatment plan [4].

Comparing AOD-9604 to Approved Adolescent Weight-Management Options

Prescribers should present FDA-approved alternatives before finalizing any off-label plan. Semaglutide 2.4 mg (Wegovy) received FDA approval in December 2022 for adolescents aged 12 and older with obesity (BMI at or above the 95th percentile) or overweight (BMI at or above the 85th percentile) with at least one weight-related comorbidity [19]. STEP TEENS (N=201) demonstrated 16.1% mean body weight reduction at 68 weeks with semaglutide versus 0.6% with placebo [8]. Orlistat 120 mg three times daily holds FDA approval for adolescents aged 12 and older; the key trial showed 0.55 kg/m2 BMI reduction versus placebo over 54 weeks in a population of 357 adolescents [20]. Neither orlistat nor semaglutide carries AOD-9604's near-total absence of human adolescent data.

Phentermine/topiramate extended-release (Qsymia) is approved for adults and has been studied in adolescents, but FDA approval in that age group as of mid-2025 is pending confirmation. Clinicians should check the current FDA label before prescribing [21].

Special Populations Within the Adolescent Range: Ages 12-14 Versus 15-17

The 12-14 age window typically corresponds to Tanner stages II-IV, the period of fastest pubertal growth. Bone age and growth velocity monitoring frequency should double in this subgroup: bone age X-ray every 3 months, not every 6 months, for the first year of any peptide therapy. The risk of epiphyseal disruption is highest when the growth spurt is most active.

Adolescents aged 15-17 who are post-pubertal (Tanner stage V) with confirmed epiphyseal closure on baseline bone age imaging carry lower growth-related risk. Monitoring can follow the standard 6-month bone age schedule. Metabolic and psychological monitoring frequency does not change regardless of pubertal stage.

Sex-based differences matter too. Girls typically complete epiphyseal closure 2-3 years earlier than boys of the same chronological age [9]. A 16-year-old girl may already have closed growth plates; a 16-year-old boy may not. Never assume closure without imaging.

Compounding Pharmacy Verification: A Mandatory Step

Not all 503A compounding pharmacies test their AOD-9604 preparations to the same standard. Before prescribing, verify that the pharmacy holds current state board of pharmacy licensure, follows USP Chapter 797 sterility standards for sterile preparations [22], and provides a certificate of analysis (CoA) with identity, purity, and potency testing from an accredited third-party laboratory. Request the CoA for every lot dispensed to an adolescent patient. Document receipt of the CoA in the patient's chart.

The FDA's 2019 guidance on compounded drug products from 503A pharmacies outlines the conditions under which compounded drugs may be dispensed [2]. Prescribers should be familiar with that document and confirm that their compounding pharmacy partner operates within its requirements.